Takeda Pharmaceutical Co (TSE:4502) Research & Development: 円675,924 Mil (TTM As of Mar. 2026)


TSE:4502 Takeda Pharmaceutical Co Ltd TSE:4502
67 GF Score
Price 円5,087.00
GF Value 円4,531.71
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Takeda Pharmaceutical Co Research & Development?

Takeda Pharmaceutical Co TSE:4502 +0.65% 67 Research & Development is 円675,924 Mil as of Mar. 2026. GuruFocus rates TSE:4502 with a GF Score™ of 67/100 and a GF Value™ of 円4,531.71 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Takeda Pharmaceutical Co's Research & Development for the three months ended in Mar. 2026 was 円195,320 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円675,924 Mil.

Takeda Pharmaceutical Co  (TSE:4502) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Takeda Pharmaceutical Co Research & Development Related Terms

Takeda Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Takeda Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Takeda Pharmaceutical Co Research & Development Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 526,087.00 633,325.00 729,924.00 730,227.00 675,924.00

Takeda Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 216,007.00 143,891.00 161,482.00 175,231.00 195,320.00
TSE:4502
67GF Score
Takeda Pharmaceutical Co Ltd TSE:4502
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Takeda Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円675,924 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円675,924 Mil mean?
Takeda Pharmaceutical Co (TSE:4502) has a Research & Development of 円675,924 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Takeda Pharmaceutical Co and its competitors.
Is Takeda Pharmaceutical Co's Research & Development too high?
Takeda Pharmaceutical Co's current Research & Development is 円675,924 Mil. Overall, Takeda Pharmaceutical Co has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's Research & Development compare to ZTS and UTHR?
Takeda Pharmaceutical Co's Research & Development of 円675,924 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Takeda Pharmaceutical Co and its competitors. Takeda Pharmaceutical Co's current Research & Development is 円675,924 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co (TSE:4502) is currently considered Modestly Overvalued. The stock's GF Value™ is 円4,531.71, compared to a current price of 円5,087.00 — trading 12.3% above its estimated fair value. The current Research & Development is 円675,924 Mil. Takeda Pharmaceutical Co's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Takeda Pharmaceutical Co (TSE:4502), the current Research & Development is 円675,924 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Takeda Pharmaceutical Co (TSE:4502) Overvalued in 2026?

Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued. The current stock price of 円5,087.00 is trading 12.3% above its estimated GF Value™ of 円4,531.71. GuruFocus considers Takeda Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TSE:4502:

  • Research & Development: 円675,924 Mil
  • GF Value™: 円4,531.71 vs. price of 円5,087.00 (12.3% above fair value)
  • GF Score™: 67/100 with 6 warning signs

No single metric tells the full story. See the TSE:4502 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Takeda Pharmaceutical Co Business Description

Address 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
67GF Score

Get the complete analysis for TSE:4502

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円5,087.00
Price
円4,531.71
GF Value